Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > OctoPlus announces agreement with a major pharmaceutical company on its controlled release technology

Abstract:
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today that it has signed an agreement with Novartis relating to the use of OctoPlus' controlled release technology.

OctoPlus announces agreement with a major pharmaceutical company on its controlled release technology

The Netherlands | Posted on June 30th, 2010

Under the contract announced today, OctoPlus will develop, up to in vivo feasibility, a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActiveŽ. Novartis will fully reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.

Simon Sturge, CEO of OctoPlus, says: "I am delighted to see our technology being evaluated by such a prestigious company as Novartis. This along with the recent data on LocteronŽ in more than 175 patients continues to build the strong support behind our PolyActiveŽ controlled release technology and our capabilities in this area."

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

####

About OctoPlus
OctoPlus is a drug delivery company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product LocteronŽ, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

For more information, please click here

Contacts:
Rianne Roukema
Corporate Communications
telephone +31 (71) 524 1071

Investor Relations

Copyright © OctoPlus

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum states in a nano-object manipulated using a mechanical system August 3rd, 2015

Nanoparticles used to breach mucus barrier in lungs: Proof-of-concept study conducted in mice a key step toward better treatments for lung diseases August 3rd, 2015

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Nanomedicine

Nanoparticles used to breach mucus barrier in lungs: Proof-of-concept study conducted in mice a key step toward better treatments for lung diseases August 3rd, 2015

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015

Announcements

Quantum states in a nano-object manipulated using a mechanical system August 3rd, 2015

Nanoparticles used to breach mucus barrier in lungs: Proof-of-concept study conducted in mice a key step toward better treatments for lung diseases August 3rd, 2015

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Nanobiotechnology

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015

Alliances/Trade associations/Partnerships/Distributorships

Harris & Harris Group Portfolio Company, HZO, Announces Partnerships with Dell and Motorola August 1st, 2015

The National Space Society Pays Tribute to Dr. Kalam -- One Of Our Leading Lights Has Joined The Stars August 1st, 2015

Liquipel Debuts Eyesight-Saving ION-Glass Blue Light Protection for iPhones and Androids at RadioShack Stores Nationwide: Liquipel's Unique Protective Screen, Available at RadioShack, Cuts Harmful Blue Light Implicated in Macular Degeneration by 10x July 28th, 2015

Dais Analytic's Business Affiliate in China Announces Ten-Year Strategic Energy Efficiency Business Arrangement With COFCO: Dais Beijing to Perform Feasibility Study on Over 80 Buildings to Improve Efficiencies as Part of Overall Hotel Energy-Savings Project July 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project